Follicular Lymphoma clinical trials
Showing 101–137 of 137 active trials. Describe your situation to see which ones you may be eligible for.
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
- Clonal Evolution in Follicular Lymphoma
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
- A Study of ARC-02 in B-cell NHL
- A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Long-term Follow-up Study of Patients Receiving CAR-T Cells
- A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- Vaccine Responses in Patients With B Cell Malignancies
- Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
- Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
- GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
- Axatilimab + CAR-T for High-Risk Lymphoma
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.